TOKYO, Mar 13 (Pulse News Wire) – StemRIM Inc. (4599.T) reported a lower net profit of ¥928 million for the six months ended July 2026, maintaining its strong cash position of ¥6.2 billion.
The company’s research and development expenses amounted to ¥748 million during the period. Despite the lack of revenue, StemRIM secured sufficient funds for stable operations through 2028. Clinical progress continued with the completion of patient enrollment for global Phase 2b trials of Ledasumtid for acute ischemic stroke and additional Phase 2 trials for epidermolysis bullosa.
The ongoing studies aim to evaluate the efficacy and safety of Ledasumtid in treating various conditions, including chronic liver disease and osteoarthritis. Ledasumtid's pipeline includes several promising targets, such as epidermolysis bullosa and acute ischemic stroke, with plans for further expansion into other therapeutic areas. The company remains committed to advancing its regenerative medicine portfolio and securing partnerships with pharmaceutical companies worldwide.
🟡 Confidence: Standard AI-translated content.